Published in Invest Ophthalmol Vis Sci on August 29, 2008
Something new under the skin. Nat Biotechnol (2011) 1.51
Recent advances in ophthalmic drug delivery. Ther Deliv (2010) 1.31
Emerging drugs for uveitis. Expert Opin Emerg Drugs (2011) 1.08
Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci (2011) 1.07
Ocular delivery of macromolecules. J Control Release (2014) 0.91
[Anti-TNF-α treatment for uveitis. Analysis of the current situation]. Ophthalmologe (2011) 0.90
Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies. J Biol Chem (2010) 0.88
Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications. Angiogenesis (2012) 0.86
In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther (2013) 0.83
Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis. Recent Pat Biomed Eng (2012) 0.82
Potential penetration of topical ranibizumab (Lucentis) in the rabbit eye. Eye (Lond) (2011) 0.82
The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease. Sci Transl Med (2015) 0.82
Emerging therapies for noninfectious uveitis: what may be coming to the clinics. J Ophthalmol (2014) 0.80
Diffusion of protein through the human cornea. Ophthalmic Res (2012) 0.75
Efficacy of Antibody Delivery to the Retina and Optic Nerve by Topical Administration. J Ocul Pharmacol Ther (2016) 0.75
Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum (2005) 2.37
Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum (2004) 1.94
Comparison of dynamic contour tonometry with goldmann applanation tonometry. Invest Ophthalmol Vis Sci (2004) 1.78
GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology (2009) 1.67
Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea (2008) 1.51
Intraocular pressure measurements using dynamic contour tonometry after laser in situ keratomileusis. Invest Ophthalmol Vis Sci (2003) 1.48
New insights into changes in corneal thickness in healthy mountaineers during a very-high-altitude climb to Mount Muztagh Ata. Arch Ophthalmol (2010) 1.48
MoisturePlus contact lens solution as a source of acanthamoeba keratitis. Cornea (2009) 1.42
Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum (2002) 1.18
Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. J Biomed Biotechnol (2010) 1.16
Comparison and reproducibility of corneal thickness and curvature readings obtained by the Galilei and the Orbscan II analysis systems. J Cataract Refract Surg (2008) 1.11
RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res (2005) 1.11
Ocular pulse amplitude in healthy subjects as measured by dynamic contour tonometry. Arch Ophthalmol (2006) 1.09
Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105. Invest Ophthalmol Vis Sci (2010) 1.07
Metal-responsive transcription factor-1 (MTF-1) is essential for embryonic liver development and heavy metal detoxification in the adult liver. FASEB J (2004) 1.04
Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum (2005) 1.02
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther (2009) 1.02
The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. J Clin Immunol (2008) 0.99
Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv Drug Deliv Rev (2003) 0.97
Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-alpha single-chain antibody, upon topical administration to the rabbit eye. Invest Ophthalmol Vis Sci (2008) 0.97
Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Arthritis Rheum (2009) 0.97
Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum (2002) 0.96
Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum (2005) 0.96
Interleukin-1 and tumor necrosis factor antagonists attenuate ethanol-induced inhibition of bone formation in a rat model of distraction osteogenesis. J Pharmacol Exp Ther (2002) 0.93
Reproducibility of straylight measurement by C-Quant for assessment of retinal straylight using the compensation comparison method. Graefes Arch Clin Exp Ophthalmol (2011) 0.92
Ethanol-induced inhibition of bone formation in a rat model of distraction osteogenesis: a role for the tumor necrosis factor signaling axis. Alcohol Clin Exp Res (2005) 0.89
IL-1 and TNF antagonists prevent inhibition of fracture healing by ethanol in rats. Toxicol Sci (2004) 0.89
Astigmatic change in biaxial microincisional cataract surgery with enlargement of one incision: a prospective controlled study. Clin Experiment Ophthalmol (2009) 0.88
Corneal patch graft for the repair of late-onset hypotony or filtering bleb leak after trabeculectomy: a new surgical technique. J Glaucoma (2014) 0.88
Generic approach for the generation of stable humanized single-chain Fv fragments from rabbit monoclonal antibodies. J Biol Chem (2010) 0.88
Astigmatic neutrality in biaxial microincision cataract surgery. J Cataract Refract Surg (2009) 0.87
Cell growth selection system to detect extracellular and transmembrane protein interactions. Biochim Biophys Acta (2003) 0.86
Rapid detection of fungal keratitis with DNA-stabilizing FTA filter paper. Invest Ophthalmol Vis Sci (2009) 0.86
Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis. Arthritis Rheum (2002) 0.85
Visual Recovery and Endothelial Cell Survival After Descemet Stripping Automated Endothelial Keratoplasty for Failed Penetrating Keratoplasty Grafts—A Cohort Study. Cornea (2015) 0.84
Loss of metal transcription factor-1 suppresses tumor growth through enhanced matrix deposition. FASEB J (2004) 0.83
Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain. J Neuroimmunol (2009) 0.82
The evolving systemic and local biomarker milieu at different stages of disease progression in rat collagen-induced arthritis. Biomarkers (2008) 0.81
Effect of riboflavin-UVA-induced collagen cross-linking on intraocular pressure measurement. Invest Ophthalmol Vis Sci (2007) 0.80
Changes in intraocular pressure after descemet stripping automated endothelial keratoplasty: a retrospective analysis. Cornea (2015) 0.80
Assessing the efficacy of the electronic patient record system EDeR: implementation study--study protocol. BMJ Open (2013) 0.79
Local gene transfer to modulate rat corneal allograft rejection. Invest Ophthalmol Vis Sci (2005) 0.79
Penetration of a topically administered anti-tumor necrosis factor alpha antibody fragment into the anterior chamber of the human eye. Ophthalmology (2013) 0.78
ISRCTN12125882 - Influence of topical anti-VEGF (Ranibizumab) on the outcome of filtration surgery for glaucoma - Study Protocol. BMC Ophthalmol (2011) 0.78
A novel PITX2 mutation and a polymorphism in a 5-generation family with Axenfeld-Rieger anomaly and coexisting Fuchs' endothelial dystrophy. Ophthalmology (2006) 0.78
Visual recovery after corneal crosslinking for keratoconus: a 1-year follow-up study. Graefes Arch Clin Exp Ophthalmol (2012) 0.78
Monovalent antibody scFv fragments selected to modulate T-cell activation by inhibition of CD86-CD28 interaction. Protein Eng Des Sel (2007) 0.77
Repositioning of a dislocated intraocular lens during a roller-coaster ride. N Engl J Med (2003) 0.76
Ocular pulse amplitude after trabeculectomy. Graefes Arch Clin Exp Ophthalmol (2005) 0.75
Corneal Cross-Linking for Brittle Cornea Syndrome. Cornea (2015) 0.75